Medtronic key Affera™ clinical study milestones

 

• HRS late-breaking data: Interim results highlight six-month outcomes for patients treated with the Sphere-9 catheter for sustained monomorphic ventricular tachycardia (VT)
• Breakthrough device designation granted for use of the Sphere-9 catheter for treatment of VT; U.S. pivotal trial approved by FDA
• New at HRS: data show consistent durability for the Sphere-360 catheter across patient anatomies; Sphere-360 approved in CE Mark geographies
• First patients enrolled in Conquer-AF trial to evaluate the Sphere-9 catheter for repeat atrial fibrillation procedures

https://news.medtronic.com/2026-04-25-Medtronic-announces-key-Affera-TM-clinical-study-milestones-for-Sphere-9-TM-and-Sphere-360-TM-catheters-as-global-adoption-continues